Similar articles for PMID: 24747441

Year	Number of Results
2006	1
2008	5
2009	7
2010	4
2011	9
2012	14
2013	16
2014	29
2015	9
2016	5
2017	6
2018	9
2019	7
2020	8
2021	7
2022	4
2024	0

1

An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. Seguin L, et al. Nat Cell Biol. 2014 May;16(5):457-68. doi: 10.1038/ncb2953. Epub 2014 Apr 20. Nat Cell Biol. 2014. PMID: 24747441 Free PMC article.

2

Integrin β3 links therapy resistance and cancer stem cell properties.

Kannan N, Nguyen LV, Eaves CJ. Kannan N, et al. Nat Cell Biol. 2014 May;16(5):397-9. doi: 10.1038/ncb2960. Nat Cell Biol. 2014. PMID: 24914436

3

Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation.

Brown WS, Wendt MK. Brown WS, et al. Breast Cancer Res. 2014 Sep 23;16(5):448. doi: 10.1186/s13058-014-0448-0. Breast Cancer Res. 2014. PMID: 25255930 Free PMC article.

4

Targeting the Achilles' heel of drug-resistant cancer stem cells.

Seguin L, Gozo M, Weis SM, Cheresh DA. Seguin L, et al. Cell Cycle. 2014;13(13):2017-8. doi: 10.4161/cc.29460. Epub 2014 Jun 6. Cell Cycle. 2014. PMID: 24906000 Free PMC article. No abstract available.

5

Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.

Kim YJ, Baek DS, Lee S, Park D, Kang HN, Cho BC, Kim YS. Kim YJ, et al. Cancer Lett. 2019 Dec 1;466:23-34. doi: 10.1016/j.canlet.2019.09.005. Epub 2019 Sep 12. Cancer Lett. 2019. PMID: 31521695

6

Reversal of EGFR inhibitors' resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer.

He F, Wang Y, Cai W, Li M, Dong L. He F, et al. Biosci Rep. 2019 Aug 28;39(8):BSR20181259. doi: 10.1042/BSR20181259. Print 2019 Aug 30. Biosci Rep. 2019. PMID: 31316001 Free PMC article.

7

Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.

Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Segura-Carretero A, Joven J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA. Corominas-Faja B, et al. Cell Cycle. 2013 Nov 1;12(21):3390-404. doi: 10.4161/cc.26417. Epub 2013 Sep 17. Cell Cycle. 2013. PMID: 24047698 Free PMC article.

8

Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.

Cao L, Fan X, Jing W, Liang Y, Chen R, Liu Y, Zhu M, Jia R, Wang H, Zhang X, Zhang Y, Zhou X, Zhao J, Guo Y. Cao L, et al. Oncotarget. 2015 Mar 30;6(9):6627-40. doi: 10.18632/oncotarget.3113. Oncotarget. 2015. PMID: 25749383 Free PMC article.

9

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H. Diep CH, et al. Clin Cancer Res. 2011 May 1;17(9):2744-56. doi: 10.1158/1078-0432.CCR-10-2214. Epub 2011 Mar 8. Clin Cancer Res. 2011. PMID: 21385921 Free PMC article.

10

Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.

Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D. Guin S, et al. J Thorac Oncol. 2013 Dec;8(12):1492-501. doi: 10.1097/JTO.0000000000000007. J Thorac Oncol. 2013. PMID: 24389431 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

126 results

Results by year